menu

Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Susanne B. Nicholas, MD, MPH, PhD
    Professor of Medicine 
    Clinical Hypertension Specialist 
    Division of Nephrology
    David Geffen School of Medicine, UCLA
    Los Angeles, CA

    Consultant: AstraZeneca, Bayer, Boehringer Ingelheim/Lily Pharmaceuticals, Gilead Sciences Inc., Janssen Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, Inc
    Research Support: Bayer, CDC, Goldfinch Bio, NIH/NCATS, NIH/NIMHD, Terasaki Institute for Biomedical Innovation, Travere

    Martin Pollak, MD
    Professor of Medicine, Harvard Medical School
    Chief of Nephrology, Beth Israel Deaconess Medical Center
    Boston, MA

    Consulting Fees: Vertex Pharmaceuticals, Inc
    Ownership Interest: Apolo1Bio
    Receives royalties: Athena Diagnostics
    Research: Vertex Pharmaceuticals, Inc

    Reviewers/Content Planners/Authors:

    • Jenn Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Mario Trucillo has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Comprehend the epidemiology of APOL1-mediated kidney disease (AMKD), particularly its prevalence in underserved African American populations
    • Analyze causes and recognize clinical manifestations of AMKD for appropriate management
    • Evaluate clinical trial results for upcoming therapies of AMKD
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Vertex Pharmaceuticals, Inc.  

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Susanne B. Nicholas, MD, MPH, PhD
    Professor of Medicine 
    Clinical Hypertension Specialist 
    Division of Nephrology
    David Geffen School of Medicine, UCLA
    Los Angeles, CA

    Consultant: AstraZeneca, Bayer, Boehringer Ingelheim/Lily Pharmaceuticals, Gilead Sciences Inc., Janssen Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, Inc
    Research Support: Bayer, CDC, Goldfinch Bio, NIH/NCATS, NIH/NIMHD, Terasaki Institute for Biomedical Innovation, Travere

    Martin Pollak, MD
    Professor of Medicine, Harvard Medical School
    Chief of Nephrology, Beth Israel Deaconess Medical Center
    Boston, MA

    Consulting Fees: Vertex Pharmaceuticals, Inc
    Ownership Interest: Apolo1Bio
    Receives royalties: Athena Diagnostics
    Research: Vertex Pharmaceuticals, Inc

    Reviewers/Content Planners/Authors:

    • Jenn Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Mario Trucillo has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Comprehend the epidemiology of APOL1-mediated kidney disease (AMKD), particularly its prevalence in underserved African American populations
    • Analyze causes and recognize clinical manifestations of AMKD for appropriate management
    • Evaluate clinical trial results for upcoming therapies of AMKD
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Vertex Pharmaceuticals, Inc.  

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Feb 2023